Be Biopharma, Inc. has presented groundbreaking preclinical findings that underscore the potential of Engineered B Cell Medicines (BCMs) as a novel therapeutic avenue for Hypophosphatasia (HPP), a rare genetic disorder. During the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, the company showcased how BCMs, developed using CRISPR/Cas9 precision gene engineering and artificial intelligence-guided protein design, successfully produced active alkaline phosphatase (ALP), which is deficient in individuals with HPP.

Key Points of the Research:

– The research focused on modifying primary human B cells to secrete ALP, an enzyme crucial for bone mineralization, using CRISPR/Cas9 and AI-based protein design.

– Engineered BCMs demonstrated the ability to produce active ALP proteins, with significant in vitro phenotypic correction in osteoblast precursor mineralization models.

– The BCM approach could offer a less invasive, redosable, and durable alternative to the existing enzyme replacement therapy, which requires multiple weekly injections and is currently approved only for pediatric-onset forms of HPP.

Innovative Approach and Potential Impact:

The BCM technology represents a significant step forward in the field of gene and cell therapy. By utilizing a safe harbor locus, CCR5, for the insertion of the ALP gene expression cassette, and optimizing protein constructs for activity and stability via an AI-based design engine, Be Biopharma is paving the way for potentially transformative treatments not only for HPP but also for a wide range of diseases.

Rick Morgan, Chief Scientific Officer at Be Biopharma, emphasized the study’s implications: “This study demonstrates how BCMs coupled with artificial intelligence-guided protein design broaden the potential of our medicines to express highly effective conjugated therapeutic proteins such as ALP-Fc fusion proteins,” he noted. He also highlighted the capability of BCMs to provide “constant and durable protein levels without preconditioning, are redosable, and can be applied to a wide range of diseases, including a potential first-in-class medicine for people living with HPP.”

Exploring the Future of BCMs:

As Be Biopharma continues to explore the capabilities of BCMs, this innovative approach could herald a new era in therapeutic biologics. The ability to engineer B cells to produce specific therapeutic proteins offers a promising platform that could be customized for various protein classes and patient populations, thereby broadening the scope of treatable conditions with cellular medicines.

The latest advancements by Be Biopharma signify a substantial leap in gene therapy technologies. By integrating AI and precise gene-editing tools, BCMs could offer more sustainable, patient-friendly treatments for genetic diseases like HPP, which currently have limited treatment options. This could greatly enhance the quality of life for patients and reduce the burden of disease management.

  AI Protein Design, ASGCT meeting highlights, Be Biopharma, CRISPR/Cas9, Engineered B Cell Medicines, genetic disorders therapy, Hypophosphatasia treatment